Analysts think CTXR stock price could increase by 554%
Jun 14, 2024, 6:29 AM
0.40%
What does CTXR do
Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, focuses on developing and commercializing critical care products in oncology and anti-infectives, including Mino-Lok and I/ONTAK for persistent cutaneous T-cell lymphoma. The company, which went public in 2017, also works on stem cell therapy and other prescription products like Halo-Lido for hemorrhoids and NoveCite for ARDS.
4 analysts think CTXR stock price will increase by 553.53%. The current median analyst target is $4.08 compared to a current stock price of $0.62. The lowest analysts target is $4.04 and the highest analyst target is $4.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
